chloroquine has been researched along with dalteparin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahuka-Mundeke, S; Bongo-Pasi Nswe, C; Hermans, MP; Ishoso, DK; Kayembe, JM; Kolié, MC; Machekano, RN; Madinga, JN; Mavungu Landu, DJ; Mbala-Kingebeni, P; Mbuyi, GM; Mellors, JW; Mills, EJ; Mofenson, L; Mukeba Tshialala, D; Mukendi, S; Muyembe-Tamfum, JJ; Nachega, JB; Nkwembe, EN; Nsio, JM; Otokoye, JO; Sam-Agudu, NA; Smith, G; Tshiasuma Pipo, M; Zumla, A | 1 |
1 other study(ies) available for chloroquine and dalteparin
| Article | Year |
|---|---|
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Democratic Republic of the Congo; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Hospitals; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Obesity; Pandemics; Patient Discharge; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2020 |